A number of other research firms have also recently weighed in on VCT. Morgan Stanley cut shares of Victrex to an underweight rating and decreased their target price for the stock from GBX 2,500 ($32.67) to GBX 2,300 ($30.05) in a research note on Friday, October 12th. Peel Hunt reaffirmed an add rating on shares of Victrex in a research note on Tuesday, December 4th. HSBC reaffirmed a hold rating on shares of Victrex in a research note on Tuesday, January 8th. UBS Group reaffirmed a buy rating and set a GBX 3,200 ($41.81) target price (down previously from GBX 3,600 ($47.04)) on shares of Victrex in a research note on Thursday, December 6th. Finally, Barclays reaffirmed an underweight rating and set a GBX 2,420 ($31.62) target price on shares of Victrex in a research note on Wednesday, December 5th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of GBX 2,630 ($34.37).
LON:VCT traded up GBX 46 ($0.60) during mid-day trading on Tuesday, reaching GBX 2,392 ($31.26). The stock had a trading volume of 242,528 shares, compared to its average volume of 274,177. Victrex has a 12 month low of GBX 1,826 ($23.86) and a 12 month high of GBX 2,772 ($36.22).
The firm also recently declared a dividend, which was paid on Friday, February 22nd. Stockholders of record on Thursday, January 31st were issued a dividend of GBX 128.82 ($1.68) per share. This represents a dividend yield of 5.46%. The ex-dividend date of this dividend was Thursday, January 31st. This is a positive change from Victrex’s previous dividend of $13.42.
In other news, insider Jakob Sigurdsson bought 3,000 shares of the company’s stock in a transaction that occurred on Monday, February 18th. The shares were acquired at an average price of GBX 2,415 ($31.56) per share, for a total transaction of £72,450 ($94,668.76). Also, insider Richard Armitage bought 1,010 shares of the company’s stock in a transaction that occurred on Wednesday, December 5th. The stock was purchased at an average price of GBX 2,318 ($30.29) per share, for a total transaction of £23,411.80 ($30,591.66). In the last quarter, insiders have bought 4,021 shares of company stock worth $9,611,166.
Victrex Company Profile
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.
Read More: Limitations of the P/E Growth ratio
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.